Roflumilast Foam 0.3% Secures Major FDA Approval to Treat Seborrheic Dermatitis

Press/Media

Period	1 Dec 2023

Media coverage

Title Roflumilast Foam 0.3% Secures Major FDA Approval to Treat Seborrheic Dermatitis
Media name/outlet Drug Topics (MJH)
Country/Territory United States
Date 1/12/23
Persons Peter Lio

Title	Roflumilast Foam 0.3% Secures Major FDA Approval to Treat Seborrheic Dermatitis
Media name/outlet	Drug Topics (MJH)
Country/Territory	United States
Date	1/12/23
Persons	Peter Lio